104 related articles for article (PubMed ID: 77089)
1. The anaphylatoxic peptide C3a of guinea pig complement. I. Purification, physicochemical and antigenetic properties.
Meuer S; Becker S; Hadding U; Bitter-Suermann D
Z Immunitatsforsch Immunobiol; 1978 Mar; 154(2):135-46. PubMed ID: 77089
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary injury induced by C3a and C5a anaphylatoxins.
Stimler NP; Hugli TE; Bloor CM
Am J Pathol; 1980 Aug; 100(2):327-48. PubMed ID: 6967702
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of a specific C3a receptor on guinea pig platelets.
Fukuoka Y; Hugli TE
J Immunol; 1988 May; 140(10):3496-501. PubMed ID: 3283237
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of C3a by a monocarboxypeptidase present in culture supernatants of stimulated guinea pig peritoneal macrophages.
Kreuzpaintner G; Damerau B; Zimmermann B; Plummer TH; Brade V
J Immunol; 1986 May; 136(9):3384-9. PubMed ID: 3485689
[TBL] [Abstract][Full Text] [Related]
5. The active site of human C4a anaphylatoxin.
Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
[TBL] [Abstract][Full Text] [Related]
6. Amino acid sequence of guinea pig C3a anaphylatoxin.
Gerard NP; Lively MO; Gerard C
Protein Seq Data Anal; 1988; 1(6):473-8. PubMed ID: 3064079
[TBL] [Abstract][Full Text] [Related]
7. Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77.
Hartung HP; Bitter-Suermann D; Hadding U
J Immunol; 1983 Mar; 130(3):1345-9. PubMed ID: 6600482
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
[TBL] [Abstract][Full Text] [Related]
10. Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels.
Marceau F; Hugli TE
J Pharmacol Exp Ther; 1984 Sep; 230(3):749-54. PubMed ID: 6332191
[TBL] [Abstract][Full Text] [Related]
11. C3a-induced contraction of guinea pig ileum consists of two components: fast histamine-mediated and slow prostanoid-mediated.
del Balzo U; Polley MJ; Levi R
J Pharmacol Exp Ther; 1989 Mar; 248(3):1003-9. PubMed ID: 2467976
[TBL] [Abstract][Full Text] [Related]
12. Human C5a des Arg increases vascular permeability.
José PJ; Forrest MJ; Williams TJ
J Immunol; 1981 Dec; 127(6):2376-80. PubMed ID: 6170701
[TBL] [Abstract][Full Text] [Related]
13. Biologic activity of a C2-derived peptide. Demonstration of a specific interaction with guinea pig lung tissues.
Cholin S; Gerard NP; Strang CJ; Davis AE
J Immunol; 1989 Apr; 142(7):2401-4. PubMed ID: 2926138
[TBL] [Abstract][Full Text] [Related]
14. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase.
Schwartz LB; Kawahara MS; Hugli TE; Vik D; Fearon DT; Austen KF
J Immunol; 1983 Apr; 130(4):1891-5. PubMed ID: 6339618
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of high-affinity binding sites for C3a anaphylatoxin on guinea-pig platelets.
Becker S; Hadding U; Schorlemmer HU; Bitter-Suermann D
Scand J Immunol; 1978; 8(6):551-5. PubMed ID: 734357
[TBL] [Abstract][Full Text] [Related]
16. Activation of the third complement component (C3) and C3a generation in cardiac anaphylaxis: histamine release and associated inotropic and chronotropic effects.
del Balzo U; Polley MJ; Levi R
J Pharmacol Exp Ther; 1988 Sep; 246(3):911-6. PubMed ID: 2458450
[TBL] [Abstract][Full Text] [Related]
17. C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets.
Zanker B; Rasokat H; Hadding U; Bitter-Suermann D
Agents Actions Suppl; 1982; 11():147-57. PubMed ID: 6983827
[TBL] [Abstract][Full Text] [Related]
18. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential.
Burger R; Zilow G; Bader A; Friedlein A; Naser W
J Immunol; 1988 Jul; 141(2):553-8. PubMed ID: 2454995
[TBL] [Abstract][Full Text] [Related]
19. Proceedings: Cleavage of the third complement component (C3) and release of a spasmogenic, C3-derived peptide (C3a) by epsilon-aminocaproic acid (EACA) in serum: a process involving the complement activating properdin system.
Vogt W; Schmidt G
Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R103. PubMed ID: 4276668
[No Abstract] [Full Text] [Related]
20. Mouse factor B of the alternative pathway of complement activation. I. Purification, characterization, and functional behavior.
Bitter-Suermann D; Burger R; Brade V; Hadding U
J Immunol; 1976 Nov; 117(5 Pt.2):1799-804. PubMed ID: 993580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
